Sama Fertility has launched SimpleIVF, described as the first fully at-home IVF and egg freezing protocol in the United States, aiming to reduce costs to $6,000 per cycle compared to the U.S. national average of $30,000. The New York-based company has raised $3.8 million from SNR Ventures, with additional investment from Ford Street Ventures, Artesian, Rootspring Ventures, and the Sequoia Scout Program.
The technology-enabled fertility care provider targets accessibility barriers affecting nearly 10 million women facing infertility in the United States. Traditional IVF requires multiple in-person visits for consultations, testing, and monitoring, with costs reaching up to $40,000 per cycle in some regions and limited insurance coverage.
“Most people either don’t live near a fertility clinic or face a system filled with upsells and delays,” said Sarthak S. Sawarkar, CEO of Sama Fertility. “A single cycle of traditional IVF can go as high as $40,000 per cycle in some regions, but with SimpleIVF we’ve brought that down to $6,000 while maintaining clinical outcomes.”
Sama’s platform uses what it calls “self-driving” fertility care, employing portable ultrasound devices and instant lab access to track patient data and automatically advance treatment steps. The company claims this approach reduces manual administrative work by over 90%, enabling clinical teams to support more patients while maintaining personalization and safety standards.
The system addresses provider shortages, with approximately 1,000 fertility doctors serving the entire United States, resulting in wait times as long as 18 months in some regions. Sama works with contracted fertility doctors and has partnered with CNY Fertility as its first clinic partner.
Clinical validation includes over 300 egg retrievals and more than 30 babies born through the platform, with Sama reporting success rates above national averages and earning SART certification. The company will present three studies at the 2025 ASRM Scientific Congress & Expo, including data on at-home ultrasound prediction capabilities and AI-driven treatment protocols.
Dr. Melvin H. Thornton II, a reproductive endocrinologist with over 25 years of experience, provided advisory support during early validation. “Through working with early users of Sama’s at-home system, I’ve seen firsthand that the outcomes consistently match – or even exceed – those from traditional clinic settings,” said Dr. Thornton.
Sama’s national waitlist opened today, with care available to patients across the United States.
